CACao

Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Liao

    Key Laboratory of Aquaculture in the South China Sea for Aquatic Economic Animal of Guangdong Higher Education Institutes, Fisheries College, Guangdong Ocean University, Zhanjiang 524088, China

    1 shared publication
  • Lin Qi

    Department of Orthopedics The Second Xiangya Hospital Central South University Changsha Hunan 410011 China

    1 shared publication
  • Maolei Shen

    Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China

    1 shared publication
  • Shankun Zhao

    Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China

    1 shared publication
  • Weizhou Wu

    Department of Urology, Maoming People’s Hospital, Maoming, China

    1 shared publication
  • Xin Li

    Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China

    1 shared publication

Latest Publications

  • Open Access

    Molecular mechanisms underlying the renal protective effects of coenzyme Q10 in acute kidney injury

    by Shankun Zhao, Weizhou Wu, Jian Liao, Xinsheng Zhang, Maolei Shen, Xin Li, Qi Lin, Chaoliang Cao

    Coenzyme Q10 (CoQ10), an endogenous antioxidant, has been reported frequently to exert an outstanding protective effect on multiple organ injury, including acute kidney injury (AKI). In this study, we aim to summarize all the current evidence of the protective action of CoQ10 against AKI as there are presently no relevant reviews in the literature. After a systematic search, 20 eligible studies, either clinical trials or experimental studies, were included and further reviewed. CoQ10 treatment exhibited a potent renal protective effect on various types of AKI, such as AKI induced by drugs (e.g., ochratoxin A, cisplatin, gentamicin, L-NAME, and nonsteroidal anti-inflammatory drug), extracorporeal shock wave lithotripsy (ESWL), sepsis, contrast media, and ischemia–reperfusion injury. The renal protective role of CoQ10 against AKI might be mediated by the antiperoxidative, anti-apoptotic, and anti-inflammatory potential of CoQ10. The molecular mechanisms for the protective effects of CoQ10 might be attributed to the regulation of multiple essential genes (e.g., caspase-3, p53, and PON1) and signaling cascades (e.g., Nrf2/HO-1 pathway). This review highlights that CoQ10 may be a potential strategy in the treatment of AKI.